Document is current
Any future updates will be listed below
-
Authors
Yoon, Isabel C.
Perez-Rojas, Stephany
Ancha, Bhavya
Elmore, Leisha C.
Mateo, Alina M.
Pichardo, Margaret S.
Tchou, Julia C.
Zhang, Jennifer Q.
Hubbard, Rebecca A.
Fayanju, Oluwadamilola M. https://orcid.org/0000-0002-0876-975X
-
Funding
Funding for this research was provided by:
National Institutes of Health (2P30CA016520, 7K08CA241390, P50CA244690)
Breast Cancer Research Foundation
Gilead Sciences
- License Information
-
More Information
Article History
Received: 19 July 2024
Accepted: 8 April 2025
First Online: 12 May 2025
Disclosures
: Oluwadamilola M. Fayanju is supported by the National Institutes of Health (NIH) under award numbers 7K08CA241390-03 (Principal Investigator [PI]: Fayanju) and P50CA244690 (PI: Schnoll), the Breast Cancer Research Foundation, and philanthropic funds from the Haas family. She also reports research support unrelated to this work from the NIH under award number U48DP006801 (PI: Fayanju) and Gilead Sciences, Inc. This work was also supported by the Electronic Phenotyping Resource (EPR) at Abramson Cancer Center under NIH award number 2P30CA016520-45 (PI: Vonderheide). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Rebecca A. Hubbard reports institutional grants from Pfizer and Merck, as well as institutional payment for teaching from Johnson & Johnson. Isabel C. Yoon, Stephany Perez-Rojas, Bhavya Ancha, Leisha C. Elmore, Alina M. Mateo, Margaret S. Pichardo, Julia C. Tchou, and Jennifer Q. Zhang have no conflicts of interest to declare that may be relevant to the contents of this study. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
